Payment overview · 2025
General Payments
$436.63
16 reported records · 12 companies
Healthcare provider profile · identity verified
Rabi U. Alam, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VAN NUYS, CA · NPI 1821288812
Verified facts
What the public records show
CMS Open Payments records show Rabi U. Alam, MD received $436.63 in general payments during 2025 across 16 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $65.92 | 15.1% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$61.42 | 14.1% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$55.46 | 12.7% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $48.29 | 11.1% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $30.59 | 7.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.31 | 6.9% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $26.80 | 6.1% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $26.78 | 6.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.86 | 5.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.44 | 5.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.96 | 4.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.80 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $436.63 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $65.92 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $61.42 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $48.29 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $30.31 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $26.80 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
254 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 254 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 235 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 221 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 70 |
| Gabapentin | Gabapentin | 193 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 156 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 150 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 36 |
| Furosemide | Furosemide | 142 | 43 |
| Omeprazole | Omeprazole | 139 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 129 | 43 |
| Lorazepam | Lorazepam | 124 | 43 |
| Metformin Hcl | Metformin Hcl | 119 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 32 |
| Levetiracetam | Levetiracetam | 89 | 24 |
| Trazodone Hcl | Trazodone Hcl | 83 | 22 |
| Famotidine | Famotidine | 82 | 30 |
| Losartan Potassium | Losartan Potassium | 74 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 15 |
| Xarelto | Rivaroxaban | 68 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 23 |
| Carvedilol | Carvedilol | 65 | 25 |
| Lactulose | Lactulose | 65 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 18 |
| Tramadol Hcl | Tramadol Hcl | 57 | 22 |
| Levofloxacin | Levofloxacin | 56 | 43 |
| Mirtazapine | Mirtazapine | 55 | 18 |
| Sodium Chloride | 0.9 % Sodium Chloride | 55 | 23 |
| Midodrine Hcl | Midodrine Hcl | 52 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 21 |
| Baclofen | Baclofen | 46 | suppressed |
| Clonazepam | Clonazepam | 45 | suppressed |
| Lisinopril | Lisinopril | 45 | 14 |
| Potassium Chloride | Potassium Chloride | 44 | 19 |
| Jardiance | Empagliflozin | 43 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 15 |
| Lacosamide | Lacosamide | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 37 | 13 |
| Glipizide | Glipizide | 37 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 19 |
| Ondansetron Odt | Ondansetron | 35 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 20 |
| Azithromycin | Azithromycin | 32 | 28 |
| Cephalexin | Cephalexin | 32 | 29 |
| Finasteride | Finasteride | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Nystatin | Nystatin | 31 | 14 |
| Epogen | Epoetin Alfa | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 20 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | 11 |
| Simvastatin | Simvastatin | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 11 |
| Alprazolam | Alprazolam | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Modafinil | Modafinil | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 17 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | 12 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | 11 |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Cuvposa | Glycopyrrolate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Meropenem | Meropenem | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $436.63 · 16 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AFREZZA, AUSTEDO XR, CAPLYTA, COBENFY, GVOKE HYPOPEN, MOUNJARO, NUZYRA, Nayzilam, VALTOCO, YUPELRI, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error